ILUVIEN marketing authorisation in Austria
Alimera Sciences has announced that the Austrian Agency for Health and Food Safety, (Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit (AGES), has granted marketing authorisation to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. 'We are excited to receive this marketing authorisation and pleased that DME patients in Austria will have this therapy available to them. We look forward to receiving the additional expected approvals from the UK and other concerned member states as we continue on track with our commercialisation plans in the EU,' said Dan Myers, president and chief executive officer, Alimera Sciences.